Litigation involving US Patent 7230012

7230012

Cases

Active

3 closed

Filed

2007–2018

Top venue

D N J

3 cases

Filing activity

Cases asserting US Patent 7230012 filed per year.

Celgene Corp. v. Hikma Pharmaceuticals International Ltd.

terminated

Docket:: 2:18-cv-13477
Court:: D.N.J.
Filed:: 2018-08-31
Terminated:: 2019-09-18

Patents:6755784 6315720 6561977 6869399 7141018 7230012 7959566 8315886 8626531

π Celgene Corp.Δ Hikma Pharmaceuticals International Ltd.

Celgene sued Hikma Pharmaceuticals International over generic lenalidomide; the asserted patents included the '784 patent and eight other patents. The case was terminated on 2019-09-18.

Celgene Corp. v. Barr Laboratories, Inc.

dismissed without prejudice

Docket:: 2:07-cv-04050
Court:: D.N.J.
Filed:: 2007-08-23
Terminated:: 2010-05-21

Patents:7230012

π Celgene Corp.Δ Barr Laboratories, Inc.

Celgene sued Barr Laboratories and others, asserting U.S. Patent 7,230,012 after Barr amended its ANDA to include a paragraph IV certification. The case was consolidated with 07-286, 07-5458, and 08-3357, and all claims/counterclaims were dismissed without prejudice by stipulation filed 2010-05-21.

Celgene Corp. v. Lannett Holdings, Inc.

Docket:: 2:15-cv-00697
Court:: D.N.J.
Filed:: 2015-01-30

Patents:7230012

π Celgene Corp.Δ Lannett Holdings, Inc.

Thalidomide ANDA litigation listed on the US 7,230,012 record. Outcome not established in the retrieved sources.